Landmark PBS listing for Australians with cystic fibrosis

Australians with cystic fibrosis in Bonner will soon have access to a new treatment following the listing of Trikafta® on the Pharmaceutical Benefits Scheme (PBS).

From April 1, Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) will be available on the PBS for the first time for Australians with cystic fibrosis aged 12 years and older, who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. F508del is the most common mutation.

In Australia, one in 2,500 babies are born with cystic fibrosis and there is currently no cure.

Cystic fibrosis is a progressive, genetic disease that causes persistent lung infections. The condition is caused by genetic defects that limit the flow of chloride and water through cell membranes, resulting in a thick, sticky build-up of mucus in the lungs, pancreas, and other organs and over time limits the ability to breathe and makes it easier for germs to grow.

Trikafta® works by improving the flow of chloride and water in patients who have a certain genetic defect and helps improve lung function and breathing.

The median life expectancy for Australians with cystic fibrosis is 47 years. Tragically, this is significantly lower than the average Australian.

Federal Member for Bonner Ross Vasta MP said the listing of Trikafta® on the PBS would be welcome news to those in my local community with CF and their families.

“This is a game changer for Australians with CF in Bonner and their families,” Mr Vasta said.

“Access to Trikafta® has been out of reach for most of the population with CF, but this listing will ensure more Australians can get the treatment they need, without huge out of pocket costs.

“This just demonstrates our Government’s continued commitment to ensuring Australians can access the medicines and treatments they need, no matter where they live.”

Minister for Health and Aged Care, Greg Hunt, said the listing of Trikafta® would be life changing for many Australians with cystic fibrosis and their families.

“Without PBS subsidy, around 1,900 Australians would pay more than $250,000 a year for access to Trikafta®,” Minister Hunt said.

“This treatment is out of reach for most Australians, and now that it will be available on the PBS, patients will only pay a maximum of $42.50 per script, or as little as $6.80 with a concession card.

“I am so proud that one of the final treatments listed on the PBS under my watch as Minister for Health is Trikafta®. This listing will make access to treatment within reach for thousands of Australians with CF each year.”

Since 2013, the Coalition Government has approved more than 2,800 new and amended listings on the PBS. This is at an overall investment by Government of $15 billion.

The Morrison Government’s commitment to ensuring Australians can access affordable medicines, when they need them, remains rock solid.

This is a stark contrast to Mr Albanese and Labor, who when last in Government stopped listing essential medicines and treatments on the PBS.

This PBS listing has been recommended by the independent Pharmaceutical Benefits Advisory Committee.

Read More

New medicines on the PBS for Australians with MS and cancer

From 1 November the Morrison Government will invest more than $86 million over the next four years to provide greater access to life saving medicines for Australians living with Multiple Sclerosis (MS), and various forms of cancer.

MS is the most commonly acquired neurological disease in younger adults with over 25,600 Australians living with MS and over 2.3 million people affected globally.

Minister for Health Greg Hunt MP said the average age of diagnosis was only 30 and around 75 per cent of those affected with MS in Australia were female.

“There is a high clinical need for effective treatments for patients with progressive forms of relapse onset multiple sclerosis,” Minister Hunt said.

Federal Member for Bonner Ross Vasta MP said Mayzent® (siponimod) would be listed on the PBS for the first time to treat those patients with secondary progressive multiple sclerosis.

“Without PBS subsidy, these patients would pay more than $25,000 per year for treatment with approximately 800 patients benefiting from this listing each year,” Mr Vasta said.

“The PBS subsidy now means patients will only need to pay $41 per prescription, or $6.60 with a concession card.”

In addition to this listing, Australians diagnosed with a rare type of lymphoma which affects the skin will receive subsidised access to a new medication and specialised treatment from 1 November 2020, through an investment of over $11.5 million.

Cutaneous T-cell lymphoma is a type of non-Hodgkin lymphoma that affects the skin and causes an accumulation of malignant T-cells in the skin, resulting in raised, rash-like or itchy patches of skin, skin lumps or ulcers and swollen lymph nodes.

Mr Vasta said Uvadex® (methoxsalen) would be listed on the PBS for the first time for treatment of patients with erythrodermic cutaneous T-cell lymphoma who have not responded to other treatments.

“Around 75 patients per year may benefit from this listing and without this PBS subsidy, these Australians would pay more than $3400 per year,” Mr Vasta said.

Other PBS listings from 1 November ­– announced in the Budget 2020-21 – include the expanded listing of:

  • Tecentriq® and Avastin® (atezolizumab and bevacizumab) for use in combination to treat patients with advanced unresectable hepatocellular carcinoma, the most common type of primary liver cancer. An average of 500 patients per year may benefit from this. They would normally pay up to $170,000 for a course of treatment without PBS subsidy;
  • Lynparza® (olaparib) for the treatment of newly diagnosed advanced high grade epithelial ovarian, fallopian tube or primary peritoneal cancers. An average of 300 patients per year may benefit from this listing and would normally pay around $140,500 per course of treatment for this medicine.

These PBS listings have been recommended by the independent Pharmaceutical Benefits Advisory Committee.

Since 2013, the Australian Government has approved over 2,450 new or amended listings on the PBS.

This represents an average of around 30 listings or amendments per month – or one each day – at an overall investment by the Government of $11.8 billion.

The Morrison Government’s commitment to ensuring that Australians can access affordable medicines, when they need them, remains rock solid.

Read More